EUVIMEDEUVIMED entdecken
Open Access

161 Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas

Elisa Rioja-Blanco, Yara Banz, Christoph Schlapbach, Urban Novak, Tanja Chiorazzo, Nicole L Bertschi, Peter Bernhardt, Pascal V Grundler, Nicholas P van der Meulen, Michal Grzmil, Roger Schibli, Martin Behe

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.268805 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Elisa Rioja-Blanco und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland. Hauptthemen laut MEDLINE: Radioimmunotherapy, Ki-1 Antigen, Lymphoma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphoma remains a significant health concern, necessitating innovative treatment approaches. 161Tb's coemission of ultra-short-range conversion and Auger electrons, with its medium-energy β--particles, may enable the elimination of single cells and small clusters present in circulation, improving therapeutic outcomes. In this study, we compared 161Tb radioimmunotherapy targeting CD30-a receptor overexpressed in lymphomas-with 177Lu-radiolabeled therapy to evaluate the effect of 161Tb's additional emission of conversion and Auger electrons.

Methods

The ability of 161Tb- and 177Lu-radiolabeled anti-CD30 antibody (cAC10) to reduce cell viability and survival and induce DNA damage was evaluated in vitro in CD30-positive T-cell lymphoma cell lines. The biodistribution, dosimetry, and therapeutic effect of both radioimmunoconjugates were studied in a xenograft mouse model. Xenografts treated with [161Tb]Tb-cAC10 and [177Lu]Lu-cAC10 were submitted for quantitative proteomics and phosphoproteomics analyses, followed by bioinformatics analysis. Results: [161Tb]Tb-cAC10 demonstrated superior and CD30-specific cytotoxicity across a panel of T-cell lymphoma cell lines. In vivo studies showed a favorable biodistribution, with high tumor uptake (31.0 ± 7.4 percentage of injected activity per mass of tissue after 48 h) and a higher tumor-absorbed dose for 161Tb. Importantly, a single administration of the 161Tb-radiolabeled compound significantly prolonged survival time compared with an equal injected activity of [177Lu]Lu-cAC10 (median survival, 41 d vs. 21 d). Phosphoproteomic analysis revealed that both [177Lu]Lu-cAC10 and [161Tb]Tb-cAC10 induced alterations in pathways regulating DNA damage response and cell cycle, among others, with 161Tb inducing more pronounced changes than did 177Lu.

Conclusion

161Tb radioimmunotherapy was an effective therapy for CD30-positive T-cell lymphomas. To our knowledge, this is the first evaluation of this therapeutic radionuclide for the treatment of hematologic malignancies. Additionally, in vivo phosphoproteomics provided insights into the biologic processes and pathways regulated by radioimmunotherapy administration, further supporting the superior efficacy of 161Tb over 177Lu.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadioimmunotherapyKi-1 AntigenLymphomaAnimalsMiceHumansCell Line, TumorTissue DistributionRadioisotopesImmunoconjugatesXenograft Model Antitumor AssaysCell SurvivalFemale

Stichwörter der Autor:innen

161TbCD30lymphomaphosphoproteomicsradioimmunotherapy

Substanzen

Ki-1 AntigenRadioisotopesImmunoconjugates

Autor:innen und Institutionen

  • Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.
  • Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
  • Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
  • Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Zitieren

APA

Rioja-Blanco, E., Banz, Y., Schlapbach, C., Novak, U., Chiorazzo, T., Bertschi, N. L., Bernhardt, P., Grundler, P. V., van der Meulen, N. P., Grzmil, M., Schibli, R., & Behe, M. (2025). 161 Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268805

Vancouver

Rioja-Blanco E, Banz Y, Schlapbach C, Novak U, Chiorazzo T, Bertschi NL, et al. 161 Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268805

BibTeX
@article{RiojaBlanco2025,
  author = {Rioja-Blanco, Elisa and Banz, Yara and Schlapbach, Christoph and Novak, Urban and Chiorazzo, Tanja and Bertschi, Nicole L and Bernhardt, Peter and Grundler, Pascal V and van der Meulen, Nicholas P and Grzmil, Michal and Schibli, Roger and Behe, Martin},
  title = {161 Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.268805}
}
Kostenlos starten →